Genomic Vision (GV.PA) EURONEXT closes at €0.0018 on 20 Mar 2026: heavy volume signals volatility

Genomic Vision SA (GV.PA) was one of the most active names on EURONEXT today, closing at €0.0018 on 20 Mar 2026 after 38,489,238 shares traded. Volume was 2.71x the average, driving a +5.88% intraday move from €0.0017. GV.PA stock remains a high-volatility small-cap in the Healthcare diagnostics space, with a market cap of €693,191 and a sharply negative year-to-date trend. Below we analyse trading, fundamentals, technicals, a Meyka AI grade and a model forecast to frame near-term risk and opportunity.

Trading summary: GV.PA stock activity on EURONEXT

Genomic Vision (GV.PA) closed at €0.0018 on EURONEXT on 20 Mar 2026, up 5.88% from the prior close of €0.0017. The session high was €0.002 and low €0.0015. Volume hit 38,489,238 versus an average of 14,217,513, giving relative volume of 2.71. Market cap stands at €693,191 and shares outstanding are 385,105,984. This trading profile classifies GV.PA stock as highly liquid intraday but thin in market value, which amplifies price moves on news or block trades.

Catalysts and sector context behind the volume surge

The Healthcare sector has underperformed YTD (-5.46%), but diagnostics names gain sporadic attention when clinical or partnership news hits. Today’s volume likely reflects speculative buying and repositioning by retail traders rather than a specific Genomic Vision disclosure. Broader diagnostics interest was visible in AC Immune’s recent PET tracer update, which lifted attention to brain diagnostics and molecular platforms AC Immune press release. Media and sector headlines can create short-lived spikes in GV.PA stock trading.

Fundamentals and valuation for GV.PA stock

Genomic Vision reports EPS of -0.11 and a negative P/E (reported -0.02), reflecting sustained losses. Price-to-sales is 0.47, cash per share is 0.0056, and enterprise value is €2,369,191. Book value per share is negative at -0.0094, and the current ratio is 0.91, indicating limited short-term liquidity. R&D intensity is high (R&D-to-revenue ~2.08x), consistent with its medical diagnostics focus. These metrics show a small-cap development-stage company with material solvency and dilution risks for investors in GV.PA stock.

Technicals, liquidity and risk profile

GV.PA stock has fallen sharply over multiple horizons: 3M -77.78% and 1Y -96.91%. The 50-day average price (~€0.00484) and 200-day average (~€0.013997) sit well above the current price, indicating a sustained downtrend. Average daily volume is 14,217,513 but spikes create wide spreads. Year high is €0.094 and year low €0.0014, showing extreme historical volatility. Traders should expect thin bid/ask depth and high slippage on larger orders.

Meyka AI rates GV.PA with a score out of 100 and model forecast

Meyka AI rates GV.PA with a score out of 100: 62.50 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, industry metrics, financial growth, key ratios, forecasts and analyst signals. Meyka AI’s forecast model projects a 12-month target of €0.005 versus the current price €0.0018, implying an upside of 177.78%. Forecasts are model-based projections and not guarantees; they assume no immediate dilution and modest commercial progress. Investors should treat the GV.PA stock forecast as a high-uncertainty scenario given the firm’s small market cap and negative equity.

Outlook and investor considerations for GV.PA stock

Key upside catalysts for Genomic Vision include commercial adoption of FiberVision/FiberComb products, new service contracts, or strategic partnerships. The company already lists alliances such as Quest Diagnostics and research agreements with Institut Pasteur, which support commercial credibility. On the downside, funding needs, possible equity raises, and negative operating margins present dilution risk. For shorter-term traders, daily volume and volatility create trading opportunities; for longer-term investors, fundamental recovery requires demonstrable revenue growth and improved cash metrics. See broader market diagnostics news for context, for example recent equipment and contract announcements in the sector Humacyte purchase commitment. You can also find the company page on Meyka: Genomic Vision (GV.PA) on Meyka.

Final Thoughts

GV.PA stock closed at €0.0018 on 20 Mar 2026 with heavy volume, underscoring its high intra-day liquidity but extremely small market capitalisation (€693,191) and elevated risk. Fundamental metrics show negative EPS (-0.11), negative book value per share, and a sub-1 current ratio, which increases the probability of future equity funding. Meyka AI’s model projects a 12-month target of €0.005, an implied upside of 177.78% versus €0.0018, but this projection assumes no near-term dilution and measurable commercial traction. Traders seeking short-term moves can exploit volume-driven volatility, while patient investors should demand clear revenue growth and improved cash flow before increasing exposure. Remember, the Meyka AI grade (B, HOLD) reflects balanced risk/reward at present and is informational, not investment advice. Forecasts are model-based projections and not guarantees — manage position size and expect high volatility in GV.PA stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.